FDA Calls Out Ferring For Sales Aid For Prostate Cancer Drug Firmagon That Cites Reduction In PSA Levels
This article was originally published in The Pink Sheet Daily
Executive Summary
Reducing rising PSA levels in advanced prostate cancer patients is not evidence of clinical benefit, FDA’s Office of Prescription Drug Promotion says.
You may also be interested in...
Genentech Fields Overstated Claim For Boniva, DDMAC Says
The ad for the osteoporosis drug - featuring actress Sally Field and running in Parade magazine - was improperly based on a post-hoc responder analysis, DDMAC says.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.